NASDAQ:BMRA Biomerica (BMRA) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free BMRA Stock Alerts $0.57 +0.03 (+5.40%) (As of 05:45 PM ET) Add Compare Share Share Today's Range$0.53▼$0.5850-Day Range$0.53▼$0.8652-Week Range$0.50▼$2.13Volume54,548 shsAverage Volume173,145 shsMarket Capitalization$9.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Biomerica alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Biomerica Stock (NASDAQ:BMRA)Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Read More BMRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRA Stock News HeadlinesMay 13, 2024 | globenewswire.comBiomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024April 29, 2024 | globenewswire.comBiomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution AgreementApril 16, 2024 | investing.comBiomerica expands offices, secures new patentsApril 15, 2024 | globenewswire.comBiomerica provides update on inFoods® IBS expansionApril 15, 2024 | msn.comBiomerica GAAP EPS of -$0.11, revenue of $1MApril 13, 2024 | investorplace.comBMRA Stock Earnings: Biomerica Reported Results for Q3 2024April 12, 2024 | globenewswire.comBiomerica Reports Third Quarter 2024 Financial ResultsMarch 28, 2024 | globenewswire.comBiomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 ConferenceMarch 10, 2024 | morningstar.comBiomerica Inc BMRAFebruary 23, 2024 | benzinga.comBiomerica Stock (NASDAQ:BMRA), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comDiagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory BoardFebruary 21, 2024 | globenewswire.comDiagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory BoardFebruary 20, 2024 | barrons.comBiomerica Inc.February 17, 2024 | finance.yahoo.comBMRA Mar 2024 2.500 callFebruary 5, 2024 | benzinga.comBiomerica Stock (NASDAQ:BMRA) Dividends: History, Yield and DatesJanuary 23, 2024 | finance.yahoo.comDiagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at BiomericaJanuary 16, 2024 | markets.businessinsider.comBiomerica Reports Second Quarter 2024 Financial ResultsDecember 20, 2023 | finance.yahoo.comIs Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?December 19, 2023 | msn.comBiomerica swings 501(k) clearance for H. pylori bacteria diagnostic testDecember 18, 2023 | markets.businessinsider.comNasdaq Gains 100 Points; Biomerica Shares Spike HigherDecember 18, 2023 | msn.comWhy Is Diagnostics Products Focused Biomerica Stock Trading Higher Today?December 18, 2023 | finance.yahoo.comBiomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. PopulationNovember 10, 2023 | tmcnet.comBiomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16November 8, 2023 | finance.yahoo.comBiomerica Expands inFoods IBS Reach with Addition of Several New GI GroupsOctober 13, 2023 | markets.businessinsider.comREPEAT - Biomerica Reports First Quarter 2024 Financial ResultsSee More Headlines Receive BMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/12/2024Today6/10/2024Next Earnings (Estimated)8/23/2024Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:BMRA CUSIPN/A CIK73290 Webwww.biomerica.com Phone(949) 645-2111Fax949-553-1231Employees62Year Founded1971Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,140,000.00 Net Margins-117.46% Pretax Margin-116.58% Return on Equity-64.00% Return on Assets-50.95% Debt Debt-to-Equity RatioN/A Current Ratio4.44 Quick Ratio3.37 Sales & Book Value Annual Sales$5.34 million Price / Sales1.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book0.80Miscellaneous Outstanding Shares16,820,000Free Float14,551,000Market Cap$9.42 million OptionableOptionable Beta-0.97 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Zackary S. Irani (Age 58)CEO & Director Comp: $141.25kMr. Allen C. Barbieri (Age 66)Executive Vice-Chairman of the Board & Corporate Secretary Comp: $126.25kMr. Gary Lu CPA (Age 43)Principal Accounting Officer & CFO Comp: $260kMs. Lucy Liu Ph.D.Director of Manufacturing & Technical OperationsMr. Robert W. CarlsonChief Commercial OfficerKey CompetitorsSmileDirectClubNASDAQ:SDCImmuCellNASDAQ:ICCCAspira Women's HealthNASDAQ:AWHOncoCyteNASDAQ:OCXTrinity BiotechNASDAQ:TRIBView All CompetitorsInstitutional OwnershipRussell Investments Group Ltd.Bought 23,872 shares on 5/8/2024Ownership: 1.340%Fore Capital LLCBought 25,000 shares on 5/7/2024Ownership: 0.355%View All Institutional Transactions BMRA Stock Analysis - Frequently Asked Questions How have BMRA shares performed in 2024? Biomerica's stock was trading at $1.25 at the start of the year. Since then, BMRA shares have decreased by 54.4% and is now trading at $0.57. View the best growth stocks for 2024 here. Are investors shorting Biomerica? Biomerica saw a increase in short interest in May. As of May 15th, there was short interest totaling 343,400 shares, an increase of 219.7% from the April 30th total of 107,400 shares. Based on an average trading volume of 227,700 shares, the short-interest ratio is currently 1.5 days. View Biomerica's Short Interest. When is Biomerica's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 23rd 2024. View our BMRA earnings forecast. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) posted its earnings results on Friday, April, 12th. The company reported ($0.11) earnings per share (EPS) for the quarter. The firm earned $1.02 million during the quarter. Biomerica had a negative net margin of 117.46% and a negative trailing twelve-month return on equity of 64.00%. What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN). Who are Biomerica's major shareholders? Biomerica's stock is owned by many different retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (1.34%), Fore Capital LLC (0.35%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste and Zackary S Irani. View institutional ownership trends. How do I buy shares of Biomerica? Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BMRA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...Paradigm Press | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.